PL2374819T3 - Przeciwciała przeciwko MASP-2 - Google Patents

Przeciwciała przeciwko MASP-2

Info

Publication number
PL2374819T3
PL2374819T3 PL11172040T PL11172040T PL2374819T3 PL 2374819 T3 PL2374819 T3 PL 2374819T3 PL 11172040 T PL11172040 T PL 11172040T PL 11172040 T PL11172040 T PL 11172040T PL 2374819 T3 PL2374819 T3 PL 2374819T3
Authority
PL
Poland
Prior art keywords
masp
antibodies
Prior art date
Application number
PL11172040T
Other languages
English (en)
Inventor
Flemming Larsen
Ulla Wahlers
Original Assignee
Helion Biotech Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helion Biotech Aps filed Critical Helion Biotech Aps
Publication of PL2374819T3 publication Critical patent/PL2374819T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
PL11172040T 2003-05-12 2004-05-12 Przeciwciała przeciwko MASP-2 PL2374819T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200300716 2003-05-12

Publications (1)

Publication Number Publication Date
PL2374819T3 true PL2374819T3 (pl) 2017-09-29

Family

ID=33483731

Family Applications (2)

Application Number Title Priority Date Filing Date
PL11172040T PL2374819T3 (pl) 2003-05-12 2004-05-12 Przeciwciała przeciwko MASP-2
PL04732276T PL1625166T3 (pl) 2003-05-12 2004-05-12 Przeciwciała przeciwko masp-2

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL04732276T PL1625166T3 (pl) 2003-05-12 2004-05-12 Przeciwciała przeciwko masp-2

Country Status (11)

Country Link
US (8) US9096676B2 (pl)
EP (2) EP1625166B1 (pl)
CN (1) CN1798769A (pl)
CY (2) CY1116506T1 (pl)
DK (2) DK2374819T3 (pl)
ES (2) ES2629344T3 (pl)
HU (2) HUE034760T2 (pl)
PL (2) PL2374819T3 (pl)
PT (2) PT2374819T (pl)
SI (2) SI1625166T1 (pl)
WO (1) WO2004106384A1 (pl)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6969601B2 (en) * 1997-04-03 2005-11-29 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
DK2374819T3 (en) 2003-05-12 2017-06-06 Helion Biotech Aps Antibodies against MASP-2
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
AU2013201558B2 (en) * 2004-06-10 2016-03-31 Omeros Corporation Methods for treating conditions associated with MASP-2-dependent complement activation
AU2011265532B2 (en) * 2004-06-10 2014-04-24 Omeros Corporation Methods for treating conditions associated with MASP-2-dependent complement activation
EP1753456B1 (en) * 2004-06-10 2016-08-10 Omeros Corporation Methods for treating conditions associated with masp-2 dependent complement activation
US20060018896A1 (en) * 2004-06-10 2006-01-26 University Of Leicester Methods for treating conditions associated with lectin-dependent complement activation
GB0412966D0 (en) 2004-06-10 2004-07-14 Univ Leicester Genetically modified non-human mammals and cells
US8859209B2 (en) 2006-01-12 2014-10-14 Carviar Aps Reimmunization and antibody design
US8524453B2 (en) * 2006-02-10 2013-09-03 The Brigham And Woman's Hospital, Inc. Lectin complement pathway assays and related compositions and methods
EP2027158B1 (en) 2006-05-02 2012-09-19 Carviar ApS Method for immunizing an avian species
NZ588713A (en) * 2008-05-09 2012-10-26 Abbott Gmbh & Co Kg Antibodies to receptor of advanced glycation end products (rage) and uses thereof
LT2488203T (lt) 2009-10-16 2017-05-25 Omeros Corporation Išplitusios intravaskulinės koaguliacijos gydymo būdai, slopinant nuo masp-2 priklausomą komplemento aktyvinimą
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
KR20180072851A (ko) 2011-04-08 2018-06-29 유니버시티 오브 레스터 Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법
BR112013028429B1 (pt) * 2011-05-04 2022-11-08 Omeros Corporation Anticorpo monoclonal humano, molécula de ácido nucleico, cassete de expressão, célula de um microrganismo transgênico, método para gerar um anticorpo isolado, composição, uso de um anticorpo, e, artigo de fabricação
AU2013201779B2 (en) * 2011-05-04 2016-01-07 Omeros Corporation Compositions for inhibiting MASP-2 dependent complement activation
US20150017162A1 (en) * 2013-03-15 2015-01-15 Omeros Corporation Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
US20140363433A1 (en) 2013-03-15 2014-12-11 Omeros Corporation Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
CN103614341B (zh) * 2013-09-02 2016-07-13 杨旸 抗甘露糖结合凝聚素的单克隆抗体及试剂盒
KR20220053057A (ko) 2013-10-17 2022-04-28 오메로스 코포레이션 Masp-2 의존성 보체 활성화와 관련된 상태의 치료 방법
WO2016085622A1 (en) * 2014-11-25 2016-06-02 Applied Materials, Inc. Substrate processing systems, apparatus, and methods with substrate carrier and purge chamber environmental controls
JP6682653B2 (ja) 2016-01-05 2020-04-15 ユニバーシティー オブ レスター 線維症の阻害を必要とする対象において線維症を阻害するための方法
JP6865767B2 (ja) 2016-03-31 2021-04-28 オメロス コーポレーション 血管形成の阻害を必要とする対象において血管形成を阻害するための方法
JOP20190068A1 (ar) * 2016-10-13 2019-04-01 Omeros Corp طرق لتقليل البول البروتيني في خاضع بشري يعاني من الاعتلال الكلوي a الناتج عن الجلوبيولين المناعي
EP3526248A4 (en) 2016-10-17 2020-07-08 Musc Foundation for Research Development COMPOSITIONS AND METHODS FOR TREATING LESIONS OF THE CENTRAL VENEER SYSTEM
TWI818919B (zh) 2017-08-15 2023-10-21 美商歐米諾斯公司 用於治療和／ 或預防與造血幹細胞移植有關的移植物抗宿主病和／ 或瀰漫性肺泡出血和／ 或靜脈閉塞性病的方法
WO2019246367A1 (en) * 2018-06-22 2019-12-26 Omeros Corporation Compositions and methods of inhibiting masp-2 for the treatment of various thrombotic diseases and disorders
GB2583560A (en) 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
CN114585637A (zh) 2019-05-07 2022-06-03 拜耳公司 Masp抑制化合物及其用途
CA3200103A1 (en) 2020-11-04 2022-05-12 Bayer Aktiengesellschaft Masp inhibitory compounds and uses thereof
EP4011904A1 (en) 2020-12-14 2022-06-15 Bayer Aktiengesellschaft Masp inhibitory compounds and uses thereof
CN115215937B (zh) * 2021-04-15 2023-05-26 上海麦济生物技术有限公司 抗人masp-2抗体及其制备方法和应用
CN117616042A (zh) * 2021-06-30 2024-02-27 苏州创胜医药集团有限公司 新的抗masp-2抗体
CN116615544A (zh) * 2021-12-10 2023-08-18 舒泰神（北京）生物制药股份有限公司 特异性识别masp2的抗体及其应用
WO2023174039A1 (en) * 2022-03-18 2023-09-21 Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd. Masp-2-targetting antibodies and uses thereof

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US558767A (en) 1896-04-21 Oyster-dredger
US4331647A (en) * 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4394370A (en) * 1981-09-21 1983-07-19 Jefferies Steven R Bone graft material for osseous defects and method of making same
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4526909A (en) * 1984-01-09 1985-07-02 Regents Of The University Of California Polymethylmethacrylate delivery system for bone morphogenetic protein
US4563489A (en) * 1984-02-10 1986-01-07 University Of California Biodegradable organic polymer delivery system for bone morphogenetic protein
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPH0662679B2 (ja) * 1985-06-21 1994-08-17 新田ゼラチン株式会社 組織親和性コラ−ゲンとその製法
US5453566A (en) * 1986-03-28 1995-09-26 Calgene, Inc. Antisense regulation of gene expression in plant/cells
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US5270199A (en) 1987-08-20 1993-12-14 The Children's Medical Center Corporation Human mannose-binding protein
ATE115999T1 (de) 1987-12-15 1995-01-15 Gene Shears Pty Ltd Ribozyme.
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8822492D0 (en) * 1988-09-24 1988-10-26 Considine J Apparatus for removing tumours from hollow organs of body
US5211657A (en) * 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5549910A (en) * 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
JP3218637B2 (ja) * 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
US5789573A (en) * 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
JP2958076B2 (ja) * 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
LU91067I2 (fr) * 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
IL108367A0 (en) * 1993-01-27 1994-04-12 Hektoen Inst For Medical Resea Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
DK0744958T3 (da) 1994-01-31 2003-10-20 Univ Boston Polyklonale antistofbiblioteker
US5856121A (en) 1994-02-24 1999-01-05 Case Western Reserve University Growth arrest homebox gene
JPH07238100A (ja) 1994-02-25 1995-09-12 Sumitomo Electric Ind Ltd ヒトのｍａｓｐに対するモノクローナル抗体
US5741516A (en) * 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
AU4467396A (en) * 1994-12-12 1996-07-10 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain, inflammation and spasm
US6492332B1 (en) * 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
US5795587A (en) * 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5738868A (en) * 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
US5739119A (en) * 1996-11-15 1998-04-14 Galli; Rachel L. Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA
US6008017A (en) * 1997-01-02 1999-12-28 Smithkline Beecham Corporation Human cardiac/brain tolloid-like protein
US6969601B2 (en) * 1997-04-03 2005-11-29 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
US5955309A (en) 1997-06-18 1999-09-21 Smithkline Beecham Corporation Polynucleotide encoding G-protein coupled receptor (H7TBA62)
US6297024B1 (en) * 1998-10-15 2001-10-02 Cell Activation, Inc. Methods for assessing complement activation
US7273925B1 (en) * 1998-12-15 2007-09-25 Brigham And Women's Hospital, Inc. Methods and products for regulating lectin complement pathway associated complement activation
JP2002532079A (ja) 1998-12-15 2002-10-02 ザ ブライハム アンド ウイミンズ ホスピタル， インコーポレイテッド 補体活性化に関連するレクチン補体経路を調節するための方法および産物
US6235494B1 (en) * 1999-02-08 2001-05-22 The Scripps Research Institute Substrates for assessing mannan-binding protein-associated serine protease activity and methods using the substrates
CA2296792A1 (en) 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
AU3633000A (en) 1999-03-26 2000-10-16 Human Genome Sciences, Inc. Neutrokine-alpha binding proteins and methods based thereon
JP2002544286A (ja) * 1999-05-14 2002-12-24 ティール，ステフェン 免疫反応が十分に発揮し得ない個体の治療におけるマンナン結合性レクチン（ｍｂｌ）の新規適用
CA2689694A1 (en) 1999-07-21 2001-02-01 Omeros Corporation Solutions and methods for inhibition of pain, inflammation and cartilage degradation
CA2381396A1 (en) 1999-08-11 2001-02-15 Curagen Corporation Polynucleotides and polypeptides encoded thereby
CA2380979A1 (en) 1999-08-13 2001-02-22 Brigham And Women's Hospital, Inc. Inhibitors of the lectin complement pathway (lcp) and their use
US20030186419A1 (en) * 1999-12-02 2003-10-02 Jensenius Jens Christian Masp-3, a complement-fixing enzyme, and uses for it
US6649592B1 (en) * 2000-01-14 2003-11-18 Science & Technology Corporation @ Unm Peptide inhibitors of LFA-1/ICAM-1 interaction
WO2001084149A2 (en) * 2000-04-29 2001-11-08 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
SG98393A1 (en) * 2000-05-19 2003-09-19 Inst Materials Research & Eng Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
US7112414B2 (en) * 2000-07-13 2006-09-26 Jens Christian Jensenius Masp-2, a complement-fixing enzyme, and uses for it
US20020094332A1 (en) * 2001-01-18 2002-07-18 Alexion Pharmaceuticals Method of prophylaxis against large myocardial infractions
CA2454562A1 (en) * 2001-07-26 2003-02-06 Alexion Pharmaceuticals, Inc. Method of improving cognitive function
CA2473786A1 (en) 2002-01-22 2003-07-31 Alexion Pharmaceuticals, Inc. Method of prophylaxis against large myocardial infarctions
MXPA04007124A (es) 2002-02-01 2004-10-29 Omeros Corp Composiciones y metodos para la inhibicion sistemica de la degradacion del cartilago.
US7538195B2 (en) * 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
US7297348B2 (en) 2002-07-19 2007-11-20 Omeros Corporation Biodegradable triblock copolymers, synthesis methods therefore, and hydrogels and biomaterials made there from
ES2614274T3 (es) 2002-09-06 2017-05-30 Alexion Pharmaceuticals, Inc. Procedimiento de tratamiento de asma usando anticuerpos frente al componente de complemento C5
US20060275764A1 (en) * 2002-12-03 2006-12-07 Aarhus Universitet Method for determining predisposition to manifestation of immune system related diseases
US7361339B2 (en) * 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction
CN101897969B (zh) 2003-02-21 2014-04-02 健泰科生物技术公司 补体抑制剂在制备用于预防或抑制组织损伤的药物中的用途
DK2374819T3 (en) 2003-05-12 2017-06-06 Helion Biotech Aps Antibodies against MASP-2
US7482376B2 (en) * 2003-07-03 2009-01-27 3-Dimensional Pharmaceuticals, Inc. Conjugated complement cascade inhibitors
WO2005014849A2 (en) * 2003-07-03 2005-02-17 Euro-Celtique, S.A. Genes associated with responses to neuropathic pain
JP2007504805A (ja) 2003-09-05 2007-03-08 ナットイムネ・アクティーゼルスカブ Ｍａｓｐ−２結晶構造およびその使用
DK1753783T3 (en) * 2004-06-03 2014-11-17 Novlmmune Sa Anti-CD3 antibodies, and methods of use thereof
GB0412966D0 (en) 2004-06-10 2004-07-14 Univ Leicester Genetically modified non-human mammals and cells
EP1753456B1 (en) * 2004-06-10 2016-08-10 Omeros Corporation Methods for treating conditions associated with masp-2 dependent complement activation
US20060018896A1 (en) * 2004-06-10 2006-01-26 University Of Leicester Methods for treating conditions associated with lectin-dependent complement activation
CN101512008B (zh) * 2006-09-08 2015-04-01 艾伯维巴哈马有限公司 白介素-13结合蛋白

Also Published As

Publication number Publication date
CY1116506T1 (el) 2017-03-15
EP1625166B1 (en) 2015-04-08
US20200216566A1 (en) 2020-07-09
CN1798769A (zh) 2006-07-05
US9096676B2 (en) 2015-08-04
HUE024996T2 (en) 2016-01-28
DK2374819T3 (en) 2017-06-06
US11008405B2 (en) 2021-05-18
PT1625166E (pt) 2015-08-20
US20230058435A1 (en) 2023-02-23
US20070009528A1 (en) 2007-01-11
US11225526B2 (en) 2022-01-18
US11008404B2 (en) 2021-05-18
HUE034760T2 (en) 2018-02-28
EP2374819A1 (en) 2011-10-12
US20210261688A1 (en) 2021-08-26
US10189909B2 (en) 2019-01-29
WO2004106384A1 (en) 2004-12-09
EP2374819B1 (en) 2017-03-22
US20200199252A1 (en) 2020-06-25
CY1119106T1 (el) 2018-02-14
US20190144564A1 (en) 2019-05-16
ES2629344T3 (es) 2017-08-08
US20160096897A1 (en) 2016-04-07
US20210221913A1 (en) 2021-07-22
DK1625166T3 (en) 2015-07-13
SI1625166T1 (sl) 2015-08-31
PL1625166T3 (pl) 2015-08-31
PT2374819T (pt) 2017-07-04
EP1625166A1 (en) 2006-02-15
SI2374819T1 (sl) 2017-09-29
ES2541134T3 (es) 2015-07-16

Similar Documents

Publication Publication Date Title
PT1625166E (pt) Anticorpos para masp-2
EP1616881A4 (en) ANTI-MPL ANTIBODIES
IL175608A0 (en) Antibodies
PT1599504E (pt) Anticorpo modificado
IL202682A0 (en) Interleukin-10 antibodies
EP1648512A4 (en) ANTI-CD19 ANTIBODIES
ZA200604074B (en) Anti-IGFR1 antibody therapeutic combinations
IL173557A0 (en) Variable antibodies
GB0305702D0 (en) Bispecific antibodies
IL181575A0 (en) Anti-ox40l antibodies
EP1670825A4 (en) ANTIBODIES DIRECTED AGAINST AN M-CSF
IL228032A0 (en) Antibodies
SI1587542T1 (sl) Uporaba anti-cd100 protiteles
GB0420466D0 (en) Anti-glucan antibodies
AU2003218456A8 (en) Antibodies that specifically bind to gmad
IL172511A0 (en) Specific human antibodies
EP1598368A4 (en) ANTI-PCI neutralizing ANTIBODY
ZA200701952B (en) Anti-OX40L antibodies
GB0306618D0 (en) Antibody
HK1209139A1 (en) Modified antibody
GB0317974D0 (en) Novel antibodies
GB0329711D0 (en) Antibodies
GB0413479D0 (en) Novel antibodies
GB0319345D0 (en) Variable antibodies
GB0319118D0 (en) Variable antibodies